Why is the US Pharma & Biotech Pulmonology March 2026 Report useful and how should I use it?

Why is the US Pharma & Biotech Pulmonology March 2026 Report useful? Imagine being able to instantly see your competitors Market Share, Share of Spend and their top performing ad copy so you can effectively benchmark your own performance. Adthena’s PPC Market Share reports provide an instant view of performance insights across hundreds of sub-industries – so you can do just that. How to use the US Pharma & Biotech Pulmonology March 2026 Report Think of these reports as a cheat sheet for your industry’s search landscape. Check out this short article for a breakdown of each report and how they can benefit your strategy.

How often is the data updated?

Data within the US Pharma & Biotech Pulmonology March 2026 Report is aggregated every month, highlighting the most significant changes from the previous period.

How does Adthena collect this data?

We use observed data from Google’s search results pages. With 20 million Google SERPs indexed per day. Adthena forms a global index of publicly available searches on Google. On top of observed data, our data science models and patented technology expand on the insights through estimated metrics like market share, share of spend, and more. We have 12 years of historical data across industries and our custom-built AI models learn from continuously updated data every day.

How accurate is the US Pharma & Biotech Pulmonology March 2026 Report?

The US Pharma & Biotech Pulmonology March 2026 Report is powered by Adthena’s Whole Market View, which is the patented technology that drives value for our 300 enterprise customers. Our unique approach to search intelligence ingests Google’s Keyword Planner into its learning models, providing a more accurate and up-to-date view of keyword data compared to traditional panel data methods. With daily data collection and updates, Adthena offers a closer-to-real-time view of the Google Ads auction, enabling timely insights and adjustments. Adthena focuses specifically on Google Ads, providing a deep dive into the channel and offering detailed insights into its workings. By processing 10 TB of new data daily and employing AI and machine learning models to analyze millions of Google Ads searches per second, Adthena provides a comprehensive and in-depth view of the competitive landscape. Learn more about our data. Learn more about our data accuracy

Does this include mobile, desktop and Google Shopping data?

Yes. The US Pharma & Biotech Pulmonology March 2026 Report aggregates data from across both device types and Google Shopping.

Who is this US Pharma & Biotech Pulmonology March 2026 Report for?

The US Pharma & Biotech Pulmonology March 2026 Report is for enterprise brands and agencies who want quick and high-level, historical benchmarks that are easily digestible and reveal insights, trends and market winners relevant to their own industry.

Ask Arlo leverages real-time GenAI to answer customers’ questions about their own search data and receive instant, tailored responses and reports directly within the Adthena platform. With millions of Google SERPs indexed every day, Arlo never misses a trick and makes sure you’re always up to date. Learn more about Ask Arlo.

US Pharma & Biotech Pulmonology - PPC Market Share Analysis March 2026

Leveraging Adthena’s Whole Market View, this analysis explores recent trends in Google Ads for the US Pulmonology category from the last month. Our Data Analyst, Ask Arlo provides commentary on key findings.

Google AI Overview visibility for Pharma & Biotech Pulmonology US

See how often AIOs appear and how search intent is distributed across buying signals.

See more data

AIO Frequency

How often a Google AI overview appears on search terms relevant to this category.

Frequency	Percentage
Frequency	38.5765275471
	61.4234724529

38%

Complex Query Frequency

A complex query is a longer, more detailed search that often contains multiple keywords, specific conditions, or multi-part questions.

Frequency	Percentage
Frequency	17
	83

17%

Search Intent Distribution

Breakdown of search queries by their underlying goal.

Intent	Distribution
Investigational	2%
Transactional	4%
Navigational	0%
Seasonal	0%
Local	1%
Problem Solving	29%

Market Exposure

Share of Clicks for top 10 US Pharma & Biotech Pulmonology brands

Here are the Top 10 competitors in the industry by Share of Clicks for the last month.

See more data

Share of Clicks - Last month

Share of Clicks - Last month
Domain	Share of clicks
dupixenthcp.com	21.89
yupelri.com	10.88
yupelrihcp.com	10.27
fasenra.com	9.17
breztri.com	7.79
zoryvehcp.com	5.04
breztrihcp.com	4.12
templehealth.org	3.77
primatene.com	3.48
dupixent.com	2.07
others	21.52

dupixenthcp.com - 21.89%
yupelri.com - 10.88%
yupelrihcp.com - 10.27%
fasenra.com - 9.17%
breztri.com - 7.79%
zoryvehcp.com - 5.04%
breztrihcp.com - 4.12%
templehealth.org - 3.77%
primatene.com - 3.48%
dupixent.com - 2.07%
others - 21.52%

In the PPC landscape, dupixenthcp.com leads with 21.89% click share, closely followed by ‘others’ at 21.52%. Meanwhile, yupelri.com captures 10.88%, showcasing diverse advertiser presence.

Market Exposure

Share of Spend for the top 10 US Pharma & Biotech Pulmonology brands

Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.

See more data

Share of Spend - Last Month

Share of Spend - Last Month
Date	dupixenthcp.com	breztri.com	zoryvehcp.com	fasenra.com	yupelri.com	breztrihcp.com	trelegy.com	dupixent.com	yupelrihcp.com	templehealth.org
2026/03/01	20.4%	8.92%	0%	3.48%	8.95%	1.85%	0.5%	3.05%	24.22%	0.04%
2026/03/02	5.56%	4.18%	6.53%	14.84%	6.39%	1.55%	0%	2.47%	20.01%	0%
2026/03/03	21.18%	15.56%	0%	17.19%	8.01%	2.85%	0%	3.06%	13.4%	0%
2026/03/04	5.99%	13.52%	6.13%	8.12%	12.69%	2.67%	2%	0.94%	13.97%	0%
2026/03/05	10.4%	13.52%	0%	3.55%	15.73%	2.72%	1.87%	0.6%	22.48%	0%
2026/03/06	1.75%	13.18%	3.35%	2.78%	6.42%	7.36%	0.86%	1.17%	5.93%	44.05%
2026/03/07	5.75%	10.76%	13.39%	10.81%	8.95%	1.62%	1.81%	4.3%	19.57%	0%
2026/03/08	8.56%	10.98%	10.1%	2.39%	7.97%	2.76%	0.56%	0.15%	24.6%	0%
2026/03/09	20.91%	18.46%	0%	10.63%	15.91%	6%	4.07%	0.15%	8.86%	0%
2026/03/10	6.89%	21.36%	0%	6.71%	16.46%	4.28%	2.01%	0.47%	13.75%	0%
2026/03/11	17.64%	7.2%	7.98%	20.53%	4.47%	2.65%	2.22%	0%	4.37%	0%
2026/03/12	5.77%	23.77%	7.29%	10.36%	9.61%	11.79%	1.29%	7.09%	6.2%	0%
2026/03/13	13.54%	9.58%	7.56%	20.52%	9.55%	6.16%	2.84%	0%	14.35%	0%
2026/03/14	10.44%	9.59%	0%	19.7%	2.89%	5.74%	3.89%	7.63%	10.68%	0.2%
2026/03/15	8.62%	5.32%	15.07%	9.66%	15.68%	6.56%	1.29%	1.4%	8.27%	0.16%
2026/03/16	11.53%	6.72%	4.96%	18.22%	9.11%	11.26%	4.7%	0%	11.44%	0.12%
2026/03/17	9.98%	12.38%	0%	23.66%	7.99%	3.15%	9.3%	3.28%	8.44%	0.16%
2026/03/18	23.12%	9.25%	6.82%	8.32%	3.8%	13.68%	3.51%	3.92%	2.14%	0.14%
2026/03/19	32.78%	10.29%	0%	9.68%	7.84%	2.95%	6.04%	0%	8.45%	2.17%
2026/03/20	36.23%	8.38%	10.54%	3.87%	2.89%	6.59%	3.45%	0%	4.66%	0.11%
2026/03/21	40.21%	6.12%	0%	15.36%	4.49%	3.64%	6.46%	7.27%	3.32%	0.12%
2026/03/22	28.32%	5.86%	0%	6.66%	7.61%	6.59%	5.11%	8.35%	8.31%	0%
2026/03/23	45.55%	2.49%	6.2%	18.9%	3.47%	1.3%	4.45%	2.08%	2.63%	0%
2026/03/24	42.18%	9.84%	0%	10.24%	6.64%	4.23%	5.64%	0%	4.76%	0%
2026/03/25	25.48%	9.15%	0%	7.19%	10.76%	3.42%	8.42%	3.13%	11.07%	0.13%
2026/03/26	28.73%	2.79%	6.1%	8.11%	7.94%	6.69%	6.6%	0%	8.73%	0.1%
2026/03/27	39.47%	5.38%	0%	6.71%	7.14%	5.14%	6.5%	0%	12%	0.11%
2026/03/28	28.4%	14.27%	0%	4%	9.09%	11.77%	5.11%	0.69%	10.22%	0.17%
2026/03/29	46.79%	3.78%	0%	1.7%	11.15%	5.86%	4.27%	0.05%	13.34%	0.1%
2026/03/30	26.98%	11.56%	11.71%	7.42%	12.05%	2.92%	8.64%	0.2%	0.7%	0.18%
2026/03/31	27.27%	16.11%	10.43%	7.22%	5.19%	4.59%	3.03%	2.88%	0.65%	0.16%

dupixenthcp.com
breztri.com
zoryvehcp.com
fasenra.com
yupelri.com
breztrihcp.com
trelegy.com
dupixent.com
yupelrihcp.com
templehealth.org

In March 2026, dupixenthcp.com led with fluctuating spend, peaking at 46.79%. Breztri.com and fasenra.com showed varied trends, while templehealth.org had minimal impact. The month ended with dupixenthcp.com dominating.

Market Exposure

Competitor Count for US Pharma & Biotech Pulmonology

Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.

See more data

Competitor Count - Last month

Competitor Count - Last month
Date	Competitor Count
2026/03/01	34
2026/03/02	35
2026/03/03	34
2026/03/04	34
2026/03/05	31
2026/03/06	35
2026/03/07	39
2026/03/08	39
2026/03/09	36
2026/03/10	39
2026/03/11	38
2026/03/12	38
2026/03/13	37
2026/03/14	40
2026/03/15	42
2026/03/16	39
2026/03/17	39
2026/03/18	41
2026/03/19	38
2026/03/20	42
2026/03/21	34
2026/03/22	36
2026/03/23	35
2026/03/24	35
2026/03/25	36
2026/03/26	34
2026/03/27	35
2026/03/28	34
2026/03/29	35
2026/03/30	34
2026/03/31	38

March began with 34 advertisers, fluctuating slightly, peaking at 42 mid-month. The month concluded with 38 advertisers, indicating a dynamic advertising landscape.

Campaign Efficiency

Market Loss & Market Gains for US Pharma & Biotech Pulmonology

Here we’re looking at the Top 10 biggest industry movers by market share gains and losses for the last 30 days.

See more data

Market Loss & Market Gains - Last month

Market Loss & Market Gains - Last month
Name	Market Trend
dupixenthcp.com	26.11%
primatene.com	2.72%
trelegy.com	1.6%
goodrx.com	1.51%
pulmonx.com	1.11%
fasenra.com	-3.25%
yupelri.com	-3.88%
breztri.com	-3.92%
yupelrihcp.com	-4.29%
templehealth.org	-8.02%

Dupixenthcp.com soared with a 26.11% click share increase, while templehealth.org plummeted by 8.02%. Primatene.com rose by 2.72%, contrasting with yupelrihcp.com’s 4.29% decline.

Campaign Efficiency

US Pharma & Biotech Pulmonology Share of Impressions

Take a look at the Top 10 competitors in the industry by Share of Impressions over the last month.

See more data

Date	dupixenthcp.com	zoryvehcp.com	primatene.com	fasenra.com	yupelri.com	tezspire.com	breztri.com	breztrihcp.com	yupelrihcp.com	templehealth.org
2026/03/01	23.37%	0%	0%	3.59%	11.06%	0.28%	3.11%	0.94%	30.86%	0.04%
2026/03/02	2.44%	7.51%	0%	11.72%	5.71%	4.82%	1.31%	0.56%	18.56%	0%
2026/03/03	26.89%	0%	0%	18.08%	9.26%	4.13%	9.16%	1.3%	15.52%	0%
2026/03/04	6.02%	10.29%	0%	8.56%	13.85%	6.71%	5.08%	1.2%	14.35%	0%
2026/03/05	12.57%	0%	15.91%	3.04%	16.5%	0.73%	5.48%	1.51%	27.13%	0%
2026/03/06	1.79%	6.39%	0%	2.96%	7.97%	4.1%	10.22%	7.43%	8.56%	38.88%
2026/03/07	6.27%	17.71%	7.25%	9.98%	9.29%	2.96%	6.68%	0.87%	20.71%	0%
2026/03/08	9.35%	15.53%	0%	2.26%	9.96%	0.42%	4.2%	1.57%	28.19%	0%
2026/03/09	26.05%	0%	0%	12.18%	18.68%	0.49%	12.95%	5.74%	10.88%	0%
2026/03/10	9.35%	0%	0%	7.48%	21.37%	5.7%	7.52%	2.3%	19.28%	0%
2026/03/11	19.99%	10.52%	0%	20.7%	4.54%	3.46%	2.5%	1.5%	4.99%	0%
2026/03/12	6.91%	10.59%	0%	11.3%	10.84%	0.11%	21.71%	11.03%	8.05%	0%
2026/03/13	13.29%	10.4%	8.52%	21.32%	10.64%	0.11%	4.39%	4.28%	16.25%	0%
2026/03/14	12.97%	0%	0%	22.03%	3.89%	0.18%	3.62%	5.16%	17.85%	0.15%
2026/03/15	10.83%	20.5%	0%	9.66%	16.69%	9.56%	1.91%	6.16%	8.82%	0.09%
2026/03/16	13.6%	8.97%	0%	19.87%	10.98%	0.1%	1.8%	7.96%	14.68%	0.08%
2026/03/17	14.16%	0%	0%	28.36%	11.18%	0.22%	2.92%	1.58%	12.13%	0.12%
2026/03/18	27.03%	11.27%	0%	9.18%	4.81%	3.59%	2.28%	14.08%	2.78%	0.1%
2026/03/19	40.24%	0%	0%	11.85%	10.12%	3.9%	2.3%	1.86%	11.84%	1.74%
2026/03/20	40.94%	16.56%	6.78%	2.55%	3.5%	0.09%	1.85%	6.15%	4.77%	0.07%
2026/03/21	46.44%	0%	0%	19.74%	6.05%	0.1%	1.56%	2.92%	4.39%	0.08%
2026/03/22	32.36%	0%	9.4%	6.56%	9.34%	0.12%	1.77%	6.35%	10.22%	0%
2026/03/23	46.5%	9.11%	0%	21.41%	3.78%	0.1%	0.93%	0.9%	4.02%	0%
2026/03/24	45.86%	0%	10.83%	13.46%	8.11%	0.14%	1.97%	2%	6.22%	0%
2026/03/25	29.8%	0%	0%	8.5%	14.12%	4.28%	2.28%	2.28%	15.77%	0.06%
2026/03/26	25.66%	7.36%	18.09%	6.67%	7.46%	0%	0.82%	5.26%	10.25%	0.03%
2026/03/27	41.16%	0%	0%	8.09%	8.11%	3.05%	1.48%	3.9%	21.47%	0.04%
2026/03/28	36.31%	0%	0%	4.26%	13.16%	0.1%	3.65%	11.18%	12.82%	0.09%
2026/03/29	51.82%	0%	0%	1.48%	13.36%	0.1%	1.06%	5.58%	17.25%	0.04%
2026/03/30	28.38%	19.37%	0%	9.64%	15.7%	6.37%	2.72%	1.9%	0.75%	0.09%
2026/03/31	27.38%	16.38%	10.97%	7.51%	6.72%	5.39%	3.13%	2.47%	0.68%	0.07%

dupixenthcp.com
zoryvehcp.com
primatene.com
fasenra.com
yupelri.com
tezspire.com
breztri.com
breztrihcp.com
yupelrihcp.com
templehealth.org

In March 2026, dupixenthcp.com dominated with a peak impression share of 51.82% on March 29. Meanwhile, templehealth.org had a notable spike on March 6 with 38.88%. The month concluded with dupixenthcp.com leading the impression share.

Campaign Efficiency

Google Text Ad Copy Insights & Creative Trends for US Pharma & Biotech Pulmonology

Ever wondered how your rivals’ ads are doing? Here we can see the top-performing ads in the industry over the last month.

See more data

Google Text Ad Copy Insights & Creative Trends for US Pharma & Biotech Pulmonology - Last month

1
Official HCP Treatment Website - Moderate-To-Severe Asthma Prescription treatment website
FDA Approved Treatment For Patients With Moderate-To-Severe Asthma.
2
Asthma Injection Option - Severe Asthma Treatment Option Prescription treatment website
Do You Have Eosinophilic Asthma? Learn About A Treatment Option That May Be Right For You.
3
OTC Inhaler - No Prescription Needed https://www.primatene.com
The Only FDA-Approved Asthma Inhaler Available Over-The-Counter. Find Primatene® MIST Now!
4
Severe Asthma Medication - Official Patient Site
If Your Asthma Medication Isn't Providing Relief, Consider An Add-On Treatment Option.
5
YUPELRI® (revefenacin) - Find YUPELRI® (revefenacin) https://www.yupelri.com/
Stay Informed & Ask Your Doctor About YUPELRI® (revefenacin) Inhalation Solution. Learn About YUPELRI® (revefenacin) Inhalation Solution, How It Works, & Access Resources.

In the competitive landscape of asthma treatments, Dupixenthcp.com and Fasenra.com emphasize FDA-approved solutions for severe asthma, while Primatene.com offers an accessible OTC inhaler. Tezspire.com suggests add-on treatments for unrelieved symptoms, and Yupelri.com focuses on patient education and resource access.

Frequently Asked Questions

Why is the US Pharma & Biotech Pulmonology March 2026 Report useful and how should I use it?

Why is the US Pharma & Biotech Pulmonology March 2026 Report useful?

Imagine being able to instantly see your competitors Market Share, Share of Spend and their top performing ad copy so you can effectively benchmark your own performance.

Adthena’s PPC Market Share reports provide an instant view of performance insights across hundreds of sub-industries – so you can do just that.

How to use the US Pharma & Biotech Pulmonology March 2026 Report
Think of these reports as a cheat sheet for your industry’s search landscape. Check out this short article for a breakdown of each report and how they can benefit your strategy.
How often is the data updated?

Data within the US Pharma & Biotech Pulmonology March 2026 Report is aggregated every month, highlighting the most significant changes from the previous period.
How does Adthena collect this data?

We use observed data from Google’s search results pages. With 20 million Google SERPs indexed per day. Adthena forms a global index of publicly available searches on Google.

On top of observed data, our data science models and patented technology expand on the insights through estimated metrics like market share, share of spend, and more.

We have 12 years of historical data across industries and our custom-built AI models learn from continuously updated data every day.
How accurate is the US Pharma & Biotech Pulmonology March 2026 Report?

The US Pharma & Biotech Pulmonology March 2026 Report is powered by Adthena’s Whole Market View, which is the patented technology that drives value for our 300 enterprise customers.

Our unique approach to search intelligence ingests Google’s Keyword Planner into its learning models, providing a more accurate and up-to-date view of keyword data compared to traditional panel data methods.

With daily data collection and updates, Adthena offers a closer-to-real-time view of the Google Ads auction, enabling timely insights and adjustments.

Adthena focuses specifically on Google Ads, providing a deep dive into the channel and offering detailed insights into its workings. By processing 10 TB of new data daily and employing AI and machine learning models to analyze millions of Google Ads searches per second, Adthena provides a comprehensive and in-depth view of the competitive landscape.

Learn more about our data.

Learn more about our data accuracy
Does this include mobile, desktop and Google Shopping data?

Yes. The US Pharma & Biotech Pulmonology March 2026 Report aggregates data from across both device types and Google Shopping.
Who is this US Pharma & Biotech Pulmonology March 2026 Report for?

The US Pharma & Biotech Pulmonology March 2026 Report is for enterprise brands and agencies who want quick and high-level, historical benchmarks that are easily digestible and reveal insights, trends and market winners relevant to their own industry.
Can I get a custom report for my brand?

Our search consultants can introduce you to data that is specific to your organization, based on the size of the relevant search term and competitor universe, and the geographies that need monitoring.

Complete the form below to get started.
What is Ask Arlo?

Ask Arlo leverages real-time GenAI to answer customers’ questions about their own search data and receive instant, tailored responses and reports directly within the Adthena platform.

With millions of Google SERPs indexed every day, Arlo never misses a trick and makes sure you’re always up to date.

Learn more about Ask Arlo.

Customer Success Stories

the7stars achieves Google Ads PPC campaign optimization with Adthena

Leveraging Adthena's comprehensive insights, the7stars and their lottery client optimized their PPC campaigns and organic strategies, resulting in substantial cost savings and improved campaign performance. Read case study

Sage case study: 75% decrease in CPCs with Adthena

Sage, a leading UK software provider, used Adthena’s brand protection strategy to curb rising CPC costs. By identifying brand infringements and optimizing spend, they effectively strengthened their brand protection strategy and increased ROI.Read case study

Vodafone case study: Driving click share and sales with strategic insights from Adthena

Vodafone used Adthena data to optimize results from the launch of the Samsung S22 product. Combining Adthena’s Strategic Insights with Google Smart Bidding, Vodafone was able to maintain a flexible strategy that leveraged both manual and automated bidding. Leveraging Adthena’s Search Term Opportunities report also allowed Vodafone to implement 27 keyword terms across their business line, driving an increase in revenue at a positive ROAS.Read case study

Get the full picture

See this data specific to your brand performance

The data on this page is just a sample of the billions of data points we hold at Adthena. The insights generated by Ask Arlo, leverage real-time GenAI to answer questions about your search data.

Our search consultants can introduce you to Whole Market View data that is specific to your organization, based on the size of the relevant search term and competitor universe, and the locations that you need monitoring.

US Pharma & Biotech Pulmonology - PPC Market Share Analysis March 2026

Pulmonology – US

Google AI Overview visibility for Pharma & Biotech Pulmonology US

AIO Frequency

Complex Query Frequency

Search Intent Distribution

Share of Clicks for top 10 US Pharma & Biotech Pulmonology brands

Share of Spend for the top 10 US Pharma & Biotech Pulmonology brands

Competitor Count for US Pharma & Biotech Pulmonology

Market Loss & Market Gains for US Pharma & Biotech Pulmonology

US Pharma & Biotech Pulmonology Share of Impressions

Google Text Ad Copy Insights & Creative Trends for US Pharma & Biotech Pulmonology

Frequently Asked Questions

Why is the US Pharma & Biotech Pulmonology March 2026 Report useful and how should I use it?

Why is the US Pharma & Biotech Pulmonology March 2026 Report useful?

How often is the data updated?

How does Adthena collect this data?

How accurate is the US Pharma & Biotech Pulmonology March 2026 Report?

Does this include mobile, desktop and Google Shopping data?

Who is this US Pharma & Biotech Pulmonology March 2026 Report for?

Can I get a custom report for my brand?

What is Ask Arlo?

Customer Success Stories

the7stars achieves Google Ads PPC campaign optimization​ with Adthena

Sage case study: 75% decrease in CPCs with Adthena

Vodafone case study: Driving click share and sales with strategic insights from Adthena

Get the full picture

See this data specific to your brand performance

the7stars achieves Google Ads PPC campaign optimization with Adthena